Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$186.52M$186.52Mderived+4.7% vs Q4 2023 Net Income$37.96M$37.96Mderived+5.0% vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$86,648,000−9.9% Operating Incomederived$45,144,000−16.4% Operating Cash Flowderived$29,024,000+21.6% Free Cash Flowderived$16,613,000+15.2% Margins · derivedGross margin46.5%−7.5 pt vs Q4 2023
Operating margin24.2%−6.1 pt vs Q4 2023
Net margin20.4%+0.0 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 3, 2025 · 62 d after period end